Paul Haluska - Concepedia

Author

Paul Haluska

Mayo Clinic ORCID

Also Known As

G. Gard, H Paul, H. J. Paul, H. Paul, Haluska Paul, Haluska, Paul, P Haluska, P. Haluska, PAUL HALUSKA, Paul Haluska

295

Publications

7.4K

Citations

H-Index

Concepts

All Affiliations

Mayo Clinic Mayo Clinic in Arizona Mayo Clinic in Florida WinnMed Bristol-Myers Squibb (United States)

About

Paul Haluska is an author at Mayo Clinic specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	42	2.9K
2	Health Sciences	3	3	445
3	Natural Sciences	3	3	74
4	Biochemistry	3	3	74
5	Public Health	1	1	57

Paul Haluska

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
Immune-Induced Epithelial to Mesenchymal Transition <i>In vivo</i> Generates Breast Cancer Stem Cells Marta Santisteban, Jennifer M. Reiman, Michael K. Asiedu, Cancer Research Breast OncologyAdult Stem CellImmunologyTumor BiologyEpithelial-mesenchymal Transition	2009	378
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study David Olmos, Sophie Postel‐Vinay, L Rhoda Molife, The Lancet Oncology Anti-igf-1r Antibody FigitumumabMedicineImmunologyPathologyPreliminary Activity	2009	338
Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer Evanthia Galanis, Lynn C. Hartmann, William A. Cliby, Cancer Research Intraperitoneal AdministrationSynthetic VirologyImmunologyImmunoeditingPathology	2010	313
Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors Paul Haluska, Heather M. Shaw, Gretchen N. Batzel, Clinical Cancer Research	2007	266
Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer Daniel D. Karp, Luis Paz‐Ares, Silvia Novello, Journal of Clinical Oncology	2009	262
Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor Johann S. de Bono, Gerhardt Attard, Alex A. Adjei, Clinical Cancer Research	2007	193
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma Paul Haluska, F. Worden, David Olmos, Cancer Chemotherapy and Pharmacology Refractory Adrenocortical CarcinomaMedicineImmunologyPathologyImmune Checkpoint Inhibitor	2009	190
Tumorgrafts as <i>In Vivo</i> Surrogates for Women with Ovarian Cancer S. John Weroha, Marc A. Becker, Sergio Enderica-Gonzalez, Clinical Cancer Research Tumoral PathologyTumor HeterogeneityClin Cancer ResMedicineGynecology	2014	189
<i>In vitro</i> and <i>In vivo</i> Antitumor Effects of the Dual Insulin-Like Growth Factor-I/Insulin Receptor Inhibitor, BMS-554417 Paul Haluska, Joan M. Carboni, David A. Loegering, Cancer Research	2006	177
Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer Evanthia Galanis, Pamela J. Atherton, Matthew J. Maurer, Cancer Research ImmunologyImmunoeditingPathologyImmunotherapeuticsImmunotherapy	2014	172

Page 1